Faculty of Dentistry, McGill University, 3550 University St., Montreal, QC, Canada H3A 2B2.
Oral Oncol. 2013 May;49(5):431-7. doi: 10.1016/j.oraloncology.2012.12.001. Epub 2013 Jan 5.
To investigate if tailored information provision decreases symptoms of anxiety and depression in late stage Head and Neck (H&N) cancer patients.
This non-randomized, controlled trial was conducted with stage III or IV H&N cancer patients. Subjects were recruited at two academic health centers in Montreal. At the test center, subjects received the Multimode Comprehensive Tailored Information Package (MCTIP), while at the control center, they received normal information provision. Participants were evaluated using the Hospital Anxiety and Depression Scale (HADS) at baseline and 3 and 6 month later. Data were analyzed using descriptive statistics then T tests and chi square tests to compare group differences and finally mixed model analysis to test differences in outcome variables.
A total of 103 subjects were recruited and of them 96 (47 tests and 49 controls) participants completed baseline, 3 and 6 month evaluations. The test group experienced lower levels of anxiety (p = 0.001) and depression (p = 0.089) than the control group.
The subjects receiving tailored information had lower levels of anxiety than their counterparts. In addition, depression showed a reduction in the expected direction in the test group.
Our results need to be further confirmed using a randomized approach in different samples but they suggest benefits for stage III and IV H&N cancer patients receiving tailored, multi-modal information concerning their cancer.
研究定制信息提供是否会减少晚期头颈部(H&N)癌症患者的焦虑和抑郁症状。
这是一项非随机对照试验,纳入了 III 期或 IV 期 H&N 癌症患者。研究对象在蒙特利尔的两个学术医疗中心招募。在测试中心,受试者接受多模式综合定制信息包(MCTIP),而在对照组,他们接受常规信息提供。参与者在基线、3 个月和 6 个月后使用医院焦虑和抑郁量表(HADS)进行评估。使用描述性统计分析数据,然后使用 T 检验和卡方检验比较组间差异,最后使用混合模型分析测试结果变量的差异。
共招募了 103 名受试者,其中 96 名(47 名测试组和 49 名对照组)参与者完成了基线、3 个月和 6 个月的评估。测试组的焦虑水平(p = 0.001)和抑郁水平(p = 0.089)均低于对照组。
接受定制信息的受试者的焦虑水平低于对照组。此外,测试组的抑郁症状呈现出预期的降低趋势。
我们的结果需要进一步通过在不同样本中采用随机方法进行验证,但它们表明,接受有关癌症的定制、多模式信息的 III 期和 IV 期 H&N 癌症患者可能会受益。